Healthcare News, Deals, and Investments Update October 19th, 2026
by Spenser Lin
Spenser Lin No Comments
LECO_Weekly-Healthcare-News_10-19-2026Download

Healthcare Weekly News and Deals – Oct 19th, 2026

  1. Agilent Technologies (NYSE: A) has agreed to acquire digital-pathology software provider Proscia in an all-cash deal worth $240 million at closing plus up to $30 million in milestones Proscia’s enterprise software integrates slide scanners, laboratory information systems, and AI tools. The platform integrates slide scanners, laboratory information systems, image analysis, and AI tools into a single operating layer used by more than 4,000 labs, hospitals, and clinics, including 16 of the top 20 pharmaceutical companies. Trailing-twelve-month revenue exceeds $18 million. The companies have partnered since 2022. The acquisition advances Agilent’s strategy in the roughly $5 billion pathology market as laboratories continue to adopt digital workflows for clinical and research use. Digital adoption continues to expand across both diagnostic and research laboratories. (Link)
  2. Welsh, Carson, Anderson & Stowe is selling a $2.8 billion stake in the CenterWell senior primary-care joint venture to BlackRock’s (NYSE: BLK) HPS Investment Partners. $2.8 billion stake in the CenterWell senior primary-care joint venture to HPS Investment Partners, the private-credit arm of BlackRock (NYSE: BLK). The joint ventures operate nearly 150 clinics that provide value-based primary care for Medicare Advantage patients as part of Humana’s (NYSE: HUM) CenterWell business. The sale transfers a scaled senior-care platform to an institutional buyer and reflects continued capital interest in Medicare Advantage-aligned primary care models. Value-based senior primary care remains a focus for institutional capital. (Link)
  3. Blackstone (NYSE: BX) has agreed to sell ZO Skin Health to Galderma (SIX: GALD) for $1.5 billion. ZO Skin Health, founded by dermatologist Zein Obagi, generated approximately $330 million in net sales over the prior twelve months. 5 billion. The physician-dispensed brand, founded by dermatologist Zein Obagi, generated approximately $330 million in net sales over the prior twelve months and markets more than 40 products in more than 40 countries. The implied multiple is roughly 4.5x revenue. The transaction gives Galderma a scaled professional skincare brand within the medical-aesthetics category and provides Blackstone an exit. Physician-dispensed skincare continues to attract strategic buyers in medical aesthetics. (Link)
  4. Zocdoc has acquired fellow New York company Sohar Health, which automates insurance-eligibility verification, in its first-ever acquisition. Zocdoc’s appointment-booking platform connects patients to in-network providers across more than 10,000 insurance plans. Sohar automates insurance eligibility verification and in-network status checks. The combination adds automated verification directly into the booking workflow and builds on an existing partnership. Zocdoc has also integrated with Google’s Gemini and Yelp, expanding its role in healthcare-access infrastructure. Reducing verification friction supports higher conversion to completed appointments. The platform now covers verification as part of the end-to-end booking experience. (Link)
  5. Parkview Health, a 16-hospital Indiana nonprofit system, is acquiring nationwide shared-services vendor Ovation Healthcare to become its sole owner. Ovation Healthcare partners with more than 500 healthcare organizations across 48 states. Ovation offers leadership advisory, spend management, revenue cycle management, and technology services, primarily to independent and rural hospitals. Parkview will become the sole owner while Ovation continues to operate as a separate organization with its own governance. The deal extends Parkview’s operational capabilities to a national provider base. Shared-services platforms help independent hospitals achieve scale without full affiliation. Ovation’s client base spans critical-access hospitals to larger systems. (Link)
  6. Value-based-care accelerator Diverge Health is merging with Medical Home Network (MHN), a supporter of federally qualified health centers. Diverge accelerates value-based care for independent primary-care practices, while Medical Home Network supports federally qualified health centers. Medical Home Network will operate on the Diverge platform while both brands remain distinct. In 2027 the combination is expected to partner with nearly 100 FQHCs, more than 300 independent practices, and more than 20 Medicaid and Medicare partners across nine states, covering approximately 500,000 members and $3 billion in medical spending. The merger pairs independent-practice reach with specialized Medicaid and FQHC expertise. (Link)
  7. HealthpointCapital has made a significant investment in Ospitek, a provider of surgical operations and patient-flow intelligence software. Ospitek’s AI- and IoT-powered platform delivers real-time visibility across the surgical episode of care, helping hospitals and ambulatory surgery centers improve operating-room throughput and team coordination. The capital supports technology development and commercial expansion. The investment aligns with HealthpointCapital’s exclusive focus on musculoskeletal healthcare and tools that address operational inefficiencies in orthopedic and surgical settings. Operating-room efficiency tools are increasingly relevant for both hospitals and ambulatory centers. Throughput and room utilization remain key economic drivers in surgical facilities. (Link)
  8. VeloSource, backed by Interlock Equity, has landed a strategic investment from UPMC Enterprises. VeloSource, backed by Interlock Equity, has received a strategic investment from UPMC Enterprises. VeloSource is a locum tenens physician-staffing agency that operates on the Syncx workforce-technology platform. The investment from UPMC’s venture arm adds a health-system strategic partner to the ownership group. Persistent physician shortages continue to support demand for technology-enabled locum staffing. The combination of private equity and health-system insight supports further scaling of the platform. Health-system venture participation adds distribution insight alongside private equity ownership. Locum platforms that combine technology with clinical relationships continue to attract capital. (Link)
  9. Carenet Health has acquired conversational-AI patient-engagement company Orbita in its 11th acquisition. Orbita provides a conversational and agentic AI platform for patient engagement, digital front door, and care navigation, with integrations to major EHR and CRM systems. Founded in 2015, the platform has delivered more than 50 million automated interactions for over 1.5 million patients. Health systems have reported reductions in same-day cancellations and gains in patient throughput. The acquisition embeds clinical-grade agentic AI into Carenet’s technology stack. Embedding agentic AI is intended to reduce manual steps while maintaining clinical oversight. (Link)
  10. Carenet Health has acquired healthcare AI and data-engineering consultancy Invene, its 12th acquisition. Invene is a healthcare-focused AI and data-engineering consultancy founded in 2018 by James Griffin. The firm has worked with 20 Fortune 100 companies, helped launch more than 400 products reaching over one billion users, and appeared on the Inc. 5000 list. Invene will operate as a Carenet company. The addition expands Carenet’s AI strategy, data engineering, and interoperability capabilities alongside its existing engagement services. Consecutive AI acquisitions reinforce Carenet’s integrated technology and services approach. (Link)
  11. Fengate Private Equity has taken a majority stake in Florida clinical-research network Clinical Research of West Florida (CRWF). Clinical Research of West Florida operates three research facilities across Tampa and Clearwater, including a Phase I unit. CRWF operates three research facilities across Tampa and Clearwater, including a dedicated Phase I unit. The investment gives Fengate exposure to the clinical-trial site-management segment, where sponsors are consolidating trials with scaled, multi-therapeutic operators. Institutional backing is expected to support capacity expansion, additional sites, and patient-recruitment capabilities valued by pharmaceutical sponsors. Sponsors value multi-site networks for recruitment speed and operational consistency. (Link)
  12. LUX Infusion, backed by Frazier Healthcare Partners, has acquired Suite Health, entering the Colorado specialty-infusion market. Suite Health provides specialty infusion therapy for patients receiving complex and recurring treatments. The bolt-on extends LUX’s geographic footprint and fits the playbook of building regional density in site-of-care infusion. The segment continues to benefit from the shift of complex drug administration out of hospitals into lower-cost ambulatory and home settings. Ambulatory infusion continues to attract investment as a lower-cost alternative to hospital administration. (Link)
  13. Alaunos Therapeutics (NASD: TCRT) has acquired Velaris Therapeutics in an all-stock deal alongside an oversubscribed $350 million private placement led by Fairmount, with Venrock Healthcare Capital Partners, T. Rowe Price, Wellington Management, Janus Henderson Investors, Access Biotechnology, BB Biotech, Perceptive Advisors, Sirenia Capital Management and ADAR1 Capital Management. Velaris develops therapies for pulmonary arterial hypertension. Concurrently, Alaunos completed an oversubscribed private placement of Series C non-voting convertible preferred stock led by Fairmount, with participation from Venrock Healthcare Capital Partners, T. Rowe Price, Wellington, Janus Henderson, and others. The placement raised roughly $350 million in gross proceeds to fund operations into 2029 for proof-of-concept data on VLR199 and VLR360. The combination of the acquisition and financing positions Alaunos for extended clinical runway. (Link)
  14. Gilead Sciences (NASD: GILD) has licensed three solid-tumor T-cell engagers from Vir Biotechnology (NASD: VIR) in a deal worth up to $1.9 billion. Gilead is paying $90 million upfront, consisting of $65 million in cash and $25 million in equity at a 30% premium, plus tiered royalties on future sales. The assets are dual-masked T-cell engagers designed for solid tumors. The transaction expands Gilead’s oncology pipeline with early-stage assets and provides Vir with non-dilutive capital and a strategic development partner. Dual-masked engagers are designed to improve therapeutic index in solid-tumor settings. (Link)
  15. AstraZeneca (NASD: AZN) and insitro have signed an AI drug-target-discovery collaboration worth up to roughly $1.5 billion. AstraZeneca (Nasdaq: AZN) and insitro have signed an AI drug-target-discovery collaboration. AstraZeneca is paying $40 million upfront, with up to roughly $1.46 billion in potential milestones across metabolic dysfunction-associated steatohepatitis and cardiomyopathies. Insitro will use its machine-learning platform to identify novel drug targets. The deal gives AstraZeneca access to AI-enabled discovery in two high-interest disease areas and provides insitro with upfront capital plus a path to development milestones. AI-enabled target discovery is increasingly used by large pharma to expand early pipelines. (Link)
  16. First Tracks Biotherapeutics (NASD: TRAX) has raised about $200 million in a private placement from Vestal Point Capital, TCGX, Sirenia Capital Management, First Light Asset Management, Affinity Asset Advisors and Trails Edge Capital Partners. The clinical-stage biotech agreed to sell 6,106,870 shares at $32.75 per share to institutional investors, including mutual funds. Proceeds are expected to support clinical development of the company’s pipeline. The financing provides capital for ongoing programs and reflects institutional demand for clinical-stage biotech assets with near-term data catalysts. Institutional participation signals confidence in the company’s clinical-stage assets. Near-term catalysts support the valuation. The placement adds runway. (Link)
  17. Recursion Pharmaceuticals (NASD: RXRX) has priced a $200 million stock offering, with participation from Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest and Driehaus Capital Management. Recursion Pharmaceuticals (Nasdaq: RXRX) has priced a $200 million underwritten offering of 61,540,000 Class A shares at $3.25 each. Participation includes Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, and Driehaus Capital Management. The offering was oversubscribed. Proceeds will support the company’s AI-driven drug-discovery platform and clinical programs, adding balance-sheet capacity amid ongoing clinical data updates and a Sanofi partnership milestone. The follow-on strengthens the balance sheet for continued platform and clinical investment. Clinical data updates continue in parallel. Balance-sheet capacity increases. (Link)
  18. Janus Living (NYSE: JAN) has acquired the Harmony at Greensboro senior-living community for $123.5 million. The property includes independent living, assisted living, and memory care and marks Janus’s entry into North Carolina. The seller is an affiliate of Smith/Packett, which will continue to operate the community. Janus, which completed its IPO in March 2026, owns and operates its portfolio under RIDEA structures and focuses exclusively on senior housing. The acquisition expands the company’s footprint beyond its core Florida and Texas markets. (Link)
  19. TriGemX Bio and TCGX Acquisition Corp. (NASD: TCGX) have signed a definitive business combination for elismetrep. TriGemX Bio, developing elismetrep (an oral TRPM8 channel blocker for acute migraine now in Phase 3), and TCGX Acquisition Corp. (Nasdaq: TCGX) have signed a definitive business combination agreement. The combined company will trade as TriGemX Bio, Inc. under the ticker TGEM. The deal includes a $160 million PIPE at $10 per share from investors including Viking Global Investors and BVF Partners, plus approximately $86 million from the SPAC trust, for expected gross proceeds of $246 million and a post-transaction equity value of roughly $600 million. Proceeds will fund ongoing Phase 3 trials and commercial readiness. (Link)
  20. Healthspan Partners has agreed to acquire Centric Health for approximately €350 million. Healthspan Partners, a U.S. affiliate of Bon Secours Mercy Health, has agreed to acquire Centric Health, Ireland’s largest primary-care network. Centric operates 90 clinics with 420 GPs serving more than 700,000 patients and also has practices in the Netherlands and Germany. Founder and CEO Dr. Maurice Cox will retain a minority stake and continue to lead the business, with practices remaining independent under the Centric brand. The transaction, valued at approximately €350 million, is subject to Competition and Consumer Protection Commission approval. Bon Secours already operates hospitals in Ireland. (Link)
  21. Rush University System for Health and Endeavor Health have announced plans to merge. Rush University System for Health and Endeavor Health have announced their intention to combine into a single integrated academic health system. The merged organization would operate 12 hospitals and more than 400 care sites, employ more than 46,000 people, and serve more than 2 million patients annually across Northern Illinois and Northwest Indiana, with combined revenue approaching $11 billion. Endeavor has committed $1 billion over several years for community impact, academics and research, and care quality. J.P. Gallagher of Endeavor would lead the combined system. Close is targeted for early 2027, subject to regulatory review. (Link)
  22. Diazyme Laboratories has acquired the assets of Alfa Wassermann Diagnostic Technologies. Alfa Wassermann, founded in 1960 and based in West Caldwell, New Jersey, is an FDA-registered manufacturer of chemistry systems and reagents used in physician offices, hospitals, veterinary practices, and biopharma. The assets will be integrated into Diazyme’s operations. Diazyme, founded in 2000 and based in Poway, California, develops clinical diagnostic reagents for automated chemistry and immunoassay analyzers and is cGMP and ISO 13485 certified. Peter Napoli will continue to manage the Alfa Wassermann business within Diazyme. (Link)
  23. Vivos Therapeutics (NASD: VVOS) has agreed to acquire an 11% stake in SOD Sciences and a 50% interest in its proprietary test. Vivos Therapeutics (Nasdaq: VVOS) has entered into a definitive agreement to acquire an 11% fully diluted equity interest in SOD Sciences and a 50% undivided co-ownership interest in SOD’s proprietary pseudohypoxia early-warning test. Consideration is 12,000 shares of newly created Series C Convertible Preferred Stock with a stated value of $12 million; no cash is involved. The structure is intended to increase reported stockholders’ equity and support Nasdaq compliance while creating potential collaboration opportunities. The minority stake and stock-for-stock consideration keep the transaction small relative to other disclosed deals. (Link)
  24. Horizon Space Acquisition I Corp. has signed a definitive business combination with ArcheNova Biotech. Horizon Space Acquisition I Corp. has signed a definitive business combination agreement with ArcheNova Biotech, a clinical-stage company focused on MSC-derived extracellular vesicles and exosomes. The SPAC, which trades on the OTCQB, and ArcheNova will combine through a series of mergers. No transaction value or PIPE size was disclosed. ArcheNova’s lead program is a topical psoriasis candidate that has completed Phase I. The combination is expected to close in the first quarter of 2027, subject to approvals. The absence of a disclosed valuation places the deal lower in priority relative to sized SPAC transactions. (Link)

Venture Deals and Other

  1. Sunbound has raised a $24 million Series A led by TTV Capital — with Bling Capital, Fika Ventures, Live Oak Bank (NYSE: LOB) and the Ziegler Linkage Fund — and acquired Ohio-based Richter Healthcare Consultants to scale its senior-living revenue operating system. The round lifts total funding to $36 million and supports growth of its AI-powered revenue-cycle platform for senior-living and post-acute operators. Concurrently, Sunbound acquired Richter Healthcare Consultants, adding more than 25 years of skilled-nursing billing and Medicaid-eligibility expertise. Combined annualized payment volume is on track for $3 billion. The combination of software and domain expertise supports claims processing for senior-living operators. (Link)
  2. Suki has raised $90 million in Series E financing from new investors Healthier Capital, Crosslink Capital and Hercules Capital (NYSE: HTGC), with existing backers Venrock, Flare Capital Partners, Hedosophia, Philips Ventures and Zoom Ventures. The ambient clinical intelligence company will use the capital to expand beyond documentation into clinical reasoning, revenue cycle, and operational workflows. Suki serves more than 450 healthcare organizations and 30-plus technology partners. Patient encounters grew more than 190% year over year in 2026. Ambient AI adoption is expanding from documentation into broader clinical and operational workflows. (Link)
  3. Transformation Capital has led an $82 million Series C in Abby Care, joined by new investors CVS Health Ventures (CVS Health, NYSE: CVS), Frist Cressey Ventures and Pivotal Ventures and existing backers Khosla Ventures, Thrive Capital and Sequoia Capital. Transformation Capital has led an $82 million Series C in Abby Care, joined by new investors CVS Health Ventures, Frist Cressey Ventures, and Pivotal Ventures, and existing backers Khosla Ventures, Thrive Capital, and Sequoia Capital. Abby Care is an AI-powered care-at-home platform that trains and certifies family members as paid caregivers. Funds support market expansion, AI development, clinical research, and health-plan partnerships. Since its Series B in 2024, patient census has grown more than fivefold; the company now serves families across eight states. (Link)
  4. Sirona Medical has raised $40 million in Series D financing led by Avidity Partners, with participation from 8VC, GreatPoint Ventures and KLT Holdings. The cloud-native radiology software company will use the capital to reach cash-flow positivity and expand its platform. Sirona’s software is designed to modernize radiology workflows. The round supports continued product development and commercial growth in the radiology software market. Radiology software modernization remains a focus as imaging volumes and workflow complexity increase. Workflow tools remain relevant as imaging demand grows. (Link)
  5. Allara has raised $30 million led by Index Ventures and GV (Google Ventures), with new investors Camino Partners, Foreground and Family Fund. The virtual women’s-health provider, founded in 2020, lifts total funding to $75 million. Capital will accelerate enterprise partnerships and expand access to specialized care for conditions including PCOS and endometriosis. The financing supports growth of the virtual care model for women’s hormonal and reproductive health. Virtual women’s-health platforms continue to attract capital for specialized hormonal and reproductive care. (Link)
  6. Brellium has raised $23 million co-led by Left Lane Capital and First Round Capital, with Digital Health Venture Partners and prior backer Menlo Ventures, to expand its AI clinical-compliance platform. The company provides an AI clinical-compliance platform serving mental-health, autism, and post-acute providers, including Gentiva and Maxim Healthcare. Funds will expand the platform’s auditing and compliance capabilities. The raise supports scaling of AI-driven compliance tools for behavioral and post-acute providers. AI-driven compliance tools address documentation and audit requirements for behavioral and post-acute providers. Compliance automation is a focus for behavioral health operators. (Link)
  7. Hidden Variable has led an $18 million Series A in Sharp Performance, joined by Andreessen Horowitz, Commonweal Ventures, Wolfson Group, FJ Labs and the Ford Foundation. Hidden Variable has led an $18 million Series A in Sharp Performance, joined by Andreessen Horowitz, Commonweal Ventures, Wolfson Group, FJ Labs, and the Ford Foundation. Sharp Performance provides confidential performance coaching to first responders, including police officers, firefighters, and paramedics. Capital supports expansion of the coaching platform. The investment addresses mental-health and performance support for frontline emergency personnel. Performance and mental-health support for first responders is an emerging focus for specialized platforms. Specialized coaching platforms are gaining attention in emergency services. (Link)
  8. Ashvin AI has raised $16.5 million led by co-founder Mathew Mammen to automate durable medical equipment operations end to end. $16.5 million led by co-founder Mathew Mammen. The company automates durable medical equipment operations end to end, from referral to qualified order and prior authorization. Capital will expand prior-authorization capabilities and commercial reach in the DME market. The platform targets administrative inefficiencies in durable medical equipment workflows for providers and suppliers. Automating referral-to-authorization workflows reduces administrative burden in the DME supply chain.platform clears most orders without manual touch, addressing rising DME demand amid falling reimbursement and staffing shortages. (Link)
  9. Confido Health has raised a $12.5 million Series A extension led by Z47, taking its total Series A to $22.5 million, to automate healthcare administration with AI. $12.5 million Series A extension led by Z47, taking total Series A funding to $22.5 million. The company is expanding beyond AI-powered patient calls to automate connected administrative tasks across providers’ existing software systems. Capital supports product development and scaling of its CareOS platform. The extension funds broader automation of healthcare administrative workflows. CareOS expands automation beyond calls into connected administrative tasks across existing provider systems. Administrative automation continues to expand across provider workflows. The extension supports broader automation of administrative tasks. (Link)
  10. Threshold (Threshold Ventures) has led a $12 million Series A in Probably Genetic, with participation from Y Combinator and existing investors. Threshold Ventures has led a $12 million Series A in Probably Genetic, with participation from Y Combinator and existing investors. The AI platform for rare-disease research, diagnosis, and treatment brings total funding to $14 million. Capital will grow the core business and expand the dataset supporting drug discovery. The raise advances AI tools for rare-disease identification and research partnerships. Rare-disease datasets support both diagnostic identification and research partnerships with drug developers. AI tools for rare disease are attracting both clinical and research interest. (Link)
  11. Define Ventures has led an $11 million Series A in Readily, with participation from Y Combinator and the California Health Care Foundation Innovation Fund.Define Ventures has led an $11 million Series A in Readily, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. Readily’s AI regulatory-compliance platform serves health plans and healthcare organizations, connecting regulatory requirements with policies, assigned actions, and audit trails. Capital supports product expansion and commercial growth. The platform addresses compliance complexity for payers and providers. Connecting regulations to actionable policies and audit trails addresses a persistent compliance gap for payers. Regulatory complexity continues to drive demand for compliance software. (Link)
  12. Fika Ventures and Evidenced have co-led an $8 million seed round in Otter Health, the new venture from healthcare operator Keith Florance. Fika Ventures and Evidenced have co-led an $8 million seed round in Otter Health. Otter Health helps health plans and providers manage care and costs through continuous, real-time clinical review and payer-provider collaboration. The company launched to address prior-authorization and utilization-management friction. Capital supports product development and initial commercial deployment of the prior-authorization platform. Real-time clinical review aims to reduce prior-authorization friction between plans and providers. Prior-authorization platforms address a persistent operational friction point. The platform targets utilization-management friction between plans and providers. (Link)
  13. Rethink Impact has led a $7 million seed round in Allswell, with Magnify Ventures, Ulu Ventures, Hopelab Ventures and existing investors Techstars and Amboy Street Ventures. Rethink Impact has led a $7 million seed round in Allswell, with Magnify Ventures, Ulu Ventures, Hopelab Ventures, and existing investors Techstars and Amboy Street Ventures. Allswell is a behavioral-health company built for the LGBTQ+ community, offering one-on-one virtual therapy, group programs, and trauma-informed care. Capital supports expansion of virtual behavioral-health services. The raise funds growth of specialized mental-health access. Specialized virtual therapy for LGBTQ+ populations addresses access gaps in behavioral health. Virtual behavioral health for underserved populations continues to attract seed capital. (Link)
  14. Redesign Health has led a $3.75 million round in Treso, with participation from Locke Health and KCRise Fund. Redesign Health has led a $3.75 million round in Treso, with participation from Locke Health and KCRise Fund. Treso is building a financial-management operating system for healthcare providers, combining accounting, receivables, expenses, and operational finance in one platform. Capital supports product development. The financing advances integrated financial tools for multi-site healthcare organizations. Integrated financial operating systems target multi-site providers seeking unified accounting and receivables tools. Provider finance tools are consolidating accounting and receivables functions. Multi-site providers are seeking unified financial management tools. (Link)
  15. AIN Ventures has led a $3.4 million pre-seed in TechNovaTime, with Speedinvest, Multiball Capital, Negative Burn Ventures and the Techstars Follow-On Fund.AIN Ventures has led a $3.4 million pre-seed in TechNovaTime, with Speedinvest, Multiball Capital, Negative Burn Ventures, and the Techstars Follow-On Fund. TechNovaTime builds AI-powered process intelligence and digital-workforce automation to streamline administrative workflows in healthcare. Capital supports early product development and initial customer deployments. The round funds automation tools for healthcare operations. Process intelligence and digital-workforce tools aim to reduce administrative load in healthcare operations. Digital workforce automation targets repetitive administrative tasks in healthcare. Administrative automation remains a focus for healthcare operations teams. (Link)
  16. Council Capital and the Anthemis Female Innovators Lab Fund have co-led a $3.2 million pre-seed in Collective X Health, with SoGal Ventures, Emerson Collective, Muse Capital and Segal Ventures. Council Capital and the Anthemis Female Innovators Lab Fund have co-led a $3.2 million pre-seed in Collective X Health, with SoGal Ventures, Emerson Collective, Muse Capital, and Segal Ventures. Collective X Health is a B2B women’s-health intelligence platform, co-founded by Dr. Stacy Sims, offering wearables, digital-health tools, and performance data for women’s health. Capital supports platform launch and early commercial efforts. Women’s-health intelligence platforms combining wearables and data are attracting early-stage capital. Early-stage capital is supporting data-driven women’s health platforms. (Link)